1.34 USD
▼-0.06-3.96%
盘后 1.63 0.00%
2026-11-20
市值
$67.01M
市盈率
—
EPS
-1.38
股息率
—
52 周区间
1.31 – 19.40
成交量
618.01K
Beta
0.97
目标价
10.29
52W 低 1.3152W 高 19.40
价格走势
公司简介
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and ch...